ATHIRA PHARMA INC (ATHA) Stock Overview
USA - NASDAQ:ATHA - US04746L1044 - Common Stock
ATHA Key Statistics, Chart & Performance
The current stock price of ATHA is 3.83 USD. In the past month the price decreased by -3.89%. In the past year, price decreased by -10.99%.
ATHA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.24 | 722.08B | ||
| JNJ | JOHNSON & JOHNSON | 17.42 | 419.44B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 15.66 | 274.83B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.36 | 238.95B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.82 | 236.74B | ||
| MRK | MERCK & CO. INC. | 10.59 | 203.64B | ||
| PFE | PFIZER INC | 7.12 | 137.31B | ||
| SNY | SANOFI-ADR | 10.62 | 116.29B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.78 | 92.82B | ||
| GSK | GSK PLC-SPON ADR | 8.84 | 81.19B | ||
| ZTS | ZOETIS INC | 23.65 | 65.19B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.79 | 47.44B |
Related stock screener links
About ATHA
Company Profile
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 26 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. The company has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.
Company Info
ATHIRA PHARMA INC
18706 North Creek Parkway, Suite 104, Box 352141
Bothell WASHINGTON 98011 US
CEO: Leen Kawas
Employees: 26
Phone: 14256208501
ATHIRA PHARMA INC / ATHA FAQ
What is the stock price of ATHIRA PHARMA INC today?
The current stock price of ATHA is 3.83 USD. The price increased by 1.32% in the last trading session.
What is the ticker symbol for ATHIRA PHARMA INC stock?
The exchange symbol of ATHIRA PHARMA INC is ATHA and it is listed on the Nasdaq exchange.
On which exchange is ATHA stock listed?
ATHA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ATHIRA PHARMA INC stock?
7 analysts have analysed ATHA and the average price target is 0.51 USD. This implies a price decrease of -86.68% is expected in the next year compared to the current price of 3.83. Check the ATHIRA PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ATHIRA PHARMA INC worth?
ATHIRA PHARMA INC (ATHA) has a market capitalization of 151.06M USD. This makes ATHA a Micro Cap stock.
How many employees does ATHIRA PHARMA INC have?
ATHIRA PHARMA INC (ATHA) currently has 26 employees.
What are the support and resistance levels for ATHIRA PHARMA INC (ATHA) stock?
ATHIRA PHARMA INC (ATHA) has a support level at 3.66 and a resistance level at 4.11. Check the full technical report for a detailed analysis of ATHA support and resistance levels.
Should I buy ATHIRA PHARMA INC (ATHA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATHA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATHA, evaluating the profitability, health, valuation and growth aspects
- ATHIRA PHARMA INC (ATHA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ATHIRA PHARMA INC (ATHA) Sales and EPS estimates to see what analysts future expectations are.
- ATHIRA PHARMA INC (ATHA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ATHIRA PHARMA INC (ATHA) Insider and Institutional Ownership to learn about the owners and their transactions.
- ATHIRA PHARMA INC (ATHA) Stock Chart to make your own analysis
- ATHIRA PHARMA INC (ATHA) Latest news and press-releases to stay up to date.
Does ATHIRA PHARMA INC (ATHA) stock pay dividends?
ATHA does not pay a dividend.
When does ATHIRA PHARMA INC (ATHA) report earnings?
ATHIRA PHARMA INC (ATHA) will report earnings on 2025-11-05.
What is the Price/Earnings (PE) ratio of ATHIRA PHARMA INC (ATHA)?
ATHIRA PHARMA INC (ATHA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.55).
ATHA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ATHA. When comparing the yearly performance of all stocks, ATHA turns out to be only a medium performer in the overall market: it outperformed 54.87% of all stocks.
ATHA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATHA. No worries on liquidiy or solvency for ATHA as it has an excellent financial health rating, but there are worries on the profitability.
ATHA Financial Highlights
Over the last trailing twelve months ATHA reported a non-GAAP Earnings per Share(EPS) of -1.55. The EPS increased by 47.81% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -168.39% | ||
| ROE | -187.12% | ||
| Debt/Equity | 0 |
ATHA Forecast & Estimates
7 analysts have analysed ATHA and the average price target is 0.51 USD. This implies a price decrease of -86.68% is expected in the next year compared to the current price of 3.83.